Group 1: Navan, Inc. (NASDAQ:NAVN) - Navan conducted its initial public offering on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [7] - A class action has been initiated due to allegations that the Offering Documents for the IPO were false and misleading, particularly regarding increased "sales and marketing" expenses [7] - Following the revelation of these issues, Navan's shares declined over 60%, trading as low as $9.01 per share by the time the action commenced [7] Group 2: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Corcept's lead product candidate, relacorilant, is being developed for multiple indications, including hypercortisolism [7] - During the class period, Corcept represented that key clinical trials provided "powerful support" for their New Drug Application (NDA) to the FDA, claiming confidence in the approval process [7] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) regarding the NDA, leading to a stock price drop from $70.20 to $34.80, a decline of 50.4% [7]